Robert Brauer, DO
General Practice · Cleveland, OHNPI 1063401412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 388 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,318 and has fallen 77.5% since, to $522 in 2025. Among general practice clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$560
- Otsuka America Pharmaceutical, Inc.$522
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$485
- Validus Pharmaceuticals LLC$470
- plus $2K from 17 others
Across 3 payments — averaging $4893.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$15K
What the payments were for
- Food & beverage$7,00194%
- Education$4436%
- Gifts$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 87 | $1,755 |
| AbbVie(2 entities) | 72 | $1,300 |
| Johnson & Johnson | 26 | $560 |
| Otsuka America Pharmaceutical, Inc. | 33 | $522 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $485 |
| Validus Pharmaceuticals LLC | 7 | $470 |
| Lundbeck LLC | 24 | $383 |
| Vanda Pharmaceuticals Inc. | 18 | $370 |
| Sunovion Pharmaceuticals Inc. | 18 | $349 |
| Alkermes, Inc. | 20 | $309 |
| Supernus Pharmaceuticals, Inc. | 8 | $277 |
| Indivior Inc. | 11 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $118 |
| Neurocrine Biosciences, Inc. | 7 | $106 |
| Axsome Therapeutics, Inc. | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Noven Therapeutics, LLC | 2 | $30 |
| Livanova USA, Inc. | 1 | $27 |
| Almatica Pharma LLC | 1 | $18 |
| Neuronetics, Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
| Corium, LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,453 in reported general payments places this provider in the 95th percentile of 2,933 general practice providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 27 | $285,596 |
| Abilify MaintenaAripiprazole | 31 | $75,543 |
| VraylarCariprazine Hcl | 44 | $67,863 |
| Invega SustennaPaliperidone Palmitate | 21 | $62,479 |
| RexultiBrexpiprazole | 27 | $46,415 |
| SecuadoAsenapine | 22 | $31,590 |
| Aripiprazole | 169 | $16,505 |
| Lurasidone Hcl | 61 | $14,838 |
| Risperdal ConstaRisperidone Microspheres | 15 | $13,495 |
| TrintellixVortioxetine Hydrobromide | 26 | $11,799 |
| Oxcarbazepine | 113 | $4,583 |
| Quetiapine Fumarate | 219 | $3,987 |
| Buspirone Hcl | 198 | $3,745 |
| Paliperidone ErPaliperidone | 31 | $3,618 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 94 | $3,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,755 | $285,59627 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $522 | $121,95858 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $560 | $75,97436 claims |
| AbbVieVraylar | $1,300 | $67,86344 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $118 | $11,79926 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $11 | $3,18761 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,933 general practice providers in Ohio.
Other general practice in Cleveland
- Corey RaymondSalem$288K
- Heather PetroffBroadview Heights$170K
- Megan WeisenbergerCincinnati$81K
- Lundon AlbrechtMentor$77K
- Daniel WardColumbus$68K
- Ankur GuptaNorth Ridgeville$67K
- Jill BartonCanfield$48K
- Andrew SmithToledo$44K
- Steven LeungMayfield Hts$35K
- Maria van HuffelGahanna$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.